Heart rhythm medications and psilocybin.
8 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Also searched as antiarrhythmic · heart rhythm medication
01 What the evidence covers
Best evidence available per medication| 8 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZLife-threatening recurrent ventricular arrhythmias (ventricular fibrillation or unstable ventricular tachycardia)
Not studied with psilocybin; it changes heart rhythm (QT) and lasts weeks, and psilocybin briefly raises heart rate and blood pressure, so effects may add.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Heart failure (adults and children); Heart rate control in chronic atrial fibrillation
No direct interaction with psilocybin is known. Its toxicity can cause nausea, vision changes and hallucinations that look like session effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Maintenance of normal sinus rhythm after conversion of atrial fibrillation or flutter; Conversion of atrial fibrillation or flutter to normal sinus rhythm
Not studied with psilocybin; it changes heart rhythm, and psilocybin briefly raises heart rate and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Reduce risk of hospitalization for atrial fibrillation (paroxysmal or persistent AF, currently in sinus rhythm)
It may slow how the body clears psilocybin by blocking enzymes. Also, it can affect heart rhythm.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Prevention of paroxysmal supraventricular tachycardia (PSVT); Prevention of paroxysmal atrial fibrillation or flutter
This heart-rhythm medicine can itself cause irregular heartbeats; psilocybin's heart-rate rise may add to that risk.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- PropafenoneEvidence: No psilocybin data
Paroxysmal atrial fibrillation or flutter recurrence (no structural heart disease); Paroxysmal supraventricular tachycardia (PSVT) recurrence (no structural heart disease)
Not studied with psilocybin; it affects heart rhythm, and psilocybin briefly raises heart rate and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- QuinidineEvidence: No psilocybin data
Conversion of atrial fibrillation or flutter to normal rhythm; Reducing relapse into atrial fibrillation or flutter
Not studied with psilocybin; it blocks an enzyme that helps break down psilocybin, so higher levels are possible. Also, it can cause heart-rhythm (QT) effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Life-threatening ventricular arrhythmias; Maintenance of normal sinus rhythm in highly symptomatic atrial fibrillation or atrial flutter
It may dampen psilocybin's temporary rise in heart rate and blood pressure. Also, it affects heart rhythm, and stopping it suddenly can worsen heart problems.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 7 | QT-prolonging |
| 2 | Liver injury |
| 1 | Anticholinergic |
| 1 | Hypoglycemia risk |
| 1 | Lowers blood pressure or causes orthostasis |
| 1 | Withdrawal or rebound if stopped abruptly |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing each| 2 | Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. |
Records reviewed 2026-10-03 to 2026-10-04. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z